Edgar Filing: NUTRA PHARMA CORP

Unassociated Document

U.S. SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): August 6, 2010

Nutra Pharma Corp.

(Exact name of registrant as specified in its charter)

California	000-32141	91-2021600
(State or jurisdiction of	(Commission	(I.R.S. Employer
incorporation or organization)	File Number)	Identification No.)

2776 University Drive

Coral Springs, Florida 33065

(Address of principal executive offices) (Zip Code)

Registrant's telephone number: 954 509-0911

(Former name or former address, if changed since last report)

Nutra Pharma Corp. is referred to herein as “we”, “our” or “us.

Item 2.02. Results of Operations and Financial Condition

On August 6, 2010, we issued a press release announcing our sales of $150,158 for our second fiscal quarter ended June 30, 2010.

A copy of the press release is attached as Exhibit 99.1 and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit 99.1 Press Release

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

DATED: August 6, 2010

	Nutra Pharma Corp.


	/s/	Rik Deitsch
		Rik Deitsch, President, Chief Executive Officer